The 10-second takeaway
For the quarter ended March 31 (Q1), Sequenom missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP loss per share expanded.
Margins contracted across the board.
Sequenom logged revenue of $14.9 million. The nine analysts polled by S&P Capital IQ expected sales of $16.5 million on the same basis. GAAP reported sales were 10% higher than the prior-year quarter's $13.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.22. The 11 earnings estimates compiled by S&P Capital IQ averaged -$0.19 per share. GAAP EPS were -$0.22 for Q1 versus -$0.13 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 36.5%, 2,640 basis points worse than the prior-year quarter. Operating margin was -163.1%, 6,600 basis points worse than the prior-year quarter. Net margin was -163.9%, 7,010 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $19.1 million. On the bottom line, the average EPS estimate is -$0.21.
Next year's average estimate for revenue is $85.7 million. The average EPS estimate is -$0.86.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 658 members out of 714 rating the stock outperform, and 56 members rating it underperform. Among 154 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 138 give Sequenom a green thumbs-up, and 16 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sequenom is outperform, with an average price target of $6.73.
Over the decades, small-cap stocks like Sequenom have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Sequenom to My Watchlist.